Syndax Pharmaceuticals Inc (NAS:SNDX)
$ 20.28 0.17 (0.85%) Market Cap: 1.72 Bil Enterprise Value: 1.28 Bil PE Ratio: 0 PB Ratio: 3.50 GF Score: 53/100

Syndax Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 10, 2021 / 06:10PM GMT
Release Date Price: $19 (-2.71%)
Madhu Sudhan Kumar
Goldman Sachs Group, Inc., Research Division - Research Analyst

Hey, everyone. Thank you for joining us here at the Goldman Sachs Global Healthcare Conference. I'm really, really excited to be joined by the whole team from Syndax Pharmaceuticals to give us an update on kind of an interesting first half of the year heading into hopefully even more interesting second half of the year.

Questions & Answers

Madhu Sudhan Kumar
Goldman Sachs Group, Inc., Research Division - Research Analyst

So let's get started with the kind of big picture view. So team, if you could you then walk through kind of the current Syndax clinical pipeline focusing both on ongoing and kind of planned clinical trials given where you are today?

Briggs W. Morrison
Syndax Pharmaceuticals, Inc. - CEO & Director

Yes, Madhu. First, thanks so much for inviting us to participate. It's great to see you in your new assignment. We currently have 2 programs in clinical development, 5613 and axatilimab. 5613 is our Menin MLL

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot